What are Mast Cell Diseases?
Signs & Symptoms
Anaphylaxis
Testing
Treatment
Find Support
Clinical Trials
COVID-19
Mastocytosis
Cutaneous Mastocytosis Variants
Systemic Mastocytosis Variants
Mast Cell Sarcoma
Mast Cell Activation Syndromes
Hereditary Alpha Tryptasemia
How to Advocate
Pediatric Resources
Emergency Room Response Plan
Emergency Room Brochure
Emergency Alert Card
Brochures
Patient Guide
Infographics
Nutrition
Biofeedback
Treatment & Research Centers
Mission, Vision & Values
Board of Directors
Medical Advisory Board
Leadership
Careers
TMS News and Updates
Chronicle Magazine
Annual Report & Financials
Our Advocacy
Webinar Library
Presentations
Research Updates
Research Grants
Publications
Open Grants
Mast Cell Disease TeleECHO
ICD-10 Codes
Volunteer
Share Your Story
Events
Take Action
Awareness Days
Give Today
Ways to Give
Shop
Leave a Legacy
Become a Partner
Donate Your Birthday
Become a Fundraiser
Secretary
Ms. Barbara Ruby has been involved in clinical research since the early 1990s, working as both a study coordinator and sub-investigator (rater) at sites. In 1997, she started working as a clinical research associate who monitors the clinical trials at study sites and then moved into the role of project manager in the early 2000s. She has worked at small biotech companies and small and large CROs (clinical research organizations). She currently works as an oversight director, overseeing the project managers and clinical trials at PPD, part of Thermo Fisher Scientific.
Ms. Ruby started working in the Mast Cell Disease Society (TMS) in the advocacy group where she served as the chair after the former chair had to step down. She has also volunteered on the Research Committee and assisted with the needs assessment questionnaire.
Ms. Ruby came onto the board at TMS in early 2022 and is current performing in the role of secretary on the board of directors.
Ms. Ruby was diagnosed with Systemic Mastocytosis in early 2013 after having symptoms for 9 years. She is excited to bring her knowledge and experience in clinical trials to TMS and to support the development of new drugs to treat systemic mastocytosis and mast cell diseases.
Back to Board List